-
Merbromin: Practical Fluorescence Assay Workflows
2026-08-16
Merbromin combines protein-binding fluorescence, enzyme inhibition, antimicrobial activity, and experimental tissue-marking utility in one research compound. This guide translates those properties into reproducible workflows, controls, troubleshooting steps, and evidence-aware application choices.
-
Catalpol, SDF-1α/CXCR4, and Ischemic Stroke
2026-08-15
This study identifies the SDF-1α/CXCR4 axis as a mechanistic link between Catalpol treatment, neural stem cell responses, and vascular remodeling after permanent cerebral ischemia. By combining a rat permanent middle cerebral artery occlusion model with oxygen–glucose deprivation assays, the authors provide preclinical evidence that Catalpol supports both neurogenesis and angiogenesis rather than targeting neuronal survival alone.
-
Halazone and Sodium Current Inactivation in Frog Nerves
2026-08-14
The reference study showed that Halazone and hypochlorous acid strongly disrupt sodium-current inactivation in voltage-clamped frog nerve fibers, while several other oxidants produce different effects. Its comparative reagent design argues against a uniquely essential methionine residue and instead supports membrane-lipid modification as a tentative explanation for altered channel kinetics.
-
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-08-14
The reference study identifies a phenotypic small-molecule screening and nanomedicine strategy for reducing SPP1 expression in tumor-associated macrophages. Its lead modulator, CANDI460, lowered SPP1 in vitro and in vivo and reduced tumor burden across murine models, providing a complementary approach to broad macrophage depletion.
-
AAL-993: From Receptor Potency to Assay Design
2026-08-13
AAL-993 is a selective VEGF receptor inhibitor for dissecting angiogenic signaling, endothelial responses, and tumor–vascular interactions. This guide translates its kinase profile and the SFI glioma network-pharmacology study into practical assay and interpretation strategies.
-
Quizartinib (AC220): FLT3 Inhibition in AML
2026-08-13
Quizartinib, also known as AC220, is a selective FLT3 inhibitor for acute myeloid leukemia (AML) research. Its nanomolar biochemical potency, FLT3-pathway selectivity, cellular activity, and xenograft performance support mechanism-focused workflows, while resistance mutations and research-use limitations define important boundaries.
-
Cediranib (AZD2171): Designing Better Assays
2026-08-12
Cediranib (AZD2171) is a potent angiogenesis inhibitor whose pathway effects should not be confused with cell killing. This guide shows how to pair VEGFR signaling measurements with proliferation and death readouts for more interpretable cancer research.
-
Paclitaxel in Gastric Cancer Assembloid Screens
2026-08-12
Paclitaxel (Taxol) provides a mechanistically defined microtubule stress test for patient-derived gastric cancer assembloids. By comparing matched tumor organoids with stromal-containing models, researchers can distinguish direct tumor-cell sensitivity from microenvironment-mediated resistance.
-
Anlotinib hydrochloride: Angiogenesis Assay Workflows
2026-08-11
Anlotinib hydrochloride enables pathway-resolved studies of VEGFR2, PDGFRβ, and FGFR1 signaling across migration, tube formation, and ex vivo angiogenesis models. This workflow-focused guide shows how to distinguish genuine endothelial cell migration inhibition from nonspecific toxicity while extending the compound into comparative cancer research.
-
Imatinib hydrochloride: Practical Research Workflows
2026-08-11
Build more informative oncology assays with Imatinib hydrochloride, a v-Abl, c-Kit, and PDGFR-directed tool for target engagement, pathway analysis, and tumor-cell response studies. This guide combines practical dose-response workflows with a cautious, hypothesis-generating framework for evaluating kinase–phosphatase crosstalk.
-
Hydrogen Suppresses Cervical Cancer: RNA-Seq Insights
2026-08-10
Chu et al. used transcriptomic profiling alongside cellular and xenograft assays to investigate how molecular hydrogen suppresses cervical cancer. Their results associate reduced HIF-1α and NF-κB p65 signaling with lower proliferation, oxidative-stress readouts, and tumor growth, while also highlighting important limits on mechanistic and clinical interpretation.
-
Radiopathomics for Gastric Cancer Immunotherapy Response
2026-08-09
This multicenter study combines baseline CT imaging and digital H&E pathology with interpretable machine learning to predict response and prognosis in advanced gastric cancer receiving immunotherapy-based combination therapy. Its radiopathomics signature outperformed several conventional biomarkers across validation cohorts and linked treatment response with immune-regulatory biology, offering a framework for noninvasive and tissue-informed patient stratification.
-
WDR36, Glycolysis, and Human TE Differentiation
2026-08-08
A recent Advanced Science study identifies WDR36 as a regulator of human trophectoderm differentiation in blastoid models and connects its activity to glycolytic metabolism through LDHA. The work combines mouse embryo analysis, human pluripotent stem cell-derived blastoids, transcriptomics, targeted metabolomics, and protein-interaction evidence to explain how metabolic state may influence early lineage commitment.
-
PD0325901: From ERK Control to Translational Strategy
2026-08-07
PD0325901 is more than a pathway inhibitor: it is a research tool for connecting MEK-ERK signaling, proliferative state, apoptosis, and emerging telomerase biology. This thought-leadership guide shows how translational researchers can use selective MEK inhibition to build stronger mechanistic evidence, interpret genotype and cell-state context, and evaluate the still-unproven intersection between MAPK signaling and APEX2-dependent TERT expression.
-
Halazone: Mechanistic Insights and Practical Limits for Rese
2026-08-07
Explore Halazone as an antimicrobial sulfonamide derivative with unique mechanistic action in water disinfection and neurophysiology. This article delivers a critical evaluation of Halazone’s oxidative mechanisms, protocol parameters, and experimental boundaries—providing guidance beyond standard reviews.